AstraZeneca (AZN) says breast cancer trial fell short

AstraZeneca (NYSE: AZN) reported clinical trial results, showing long-term survival benefits in lung cancer treatments with Tagrisso and Enhertu, but mixed outcomes in advanced breast cancer research. Tagrisso reduced death risk by 47-48% in early-stage lung cancer, while Enhertu showed a 37% risk reduction in advanced cases. AZN shares rose 1.86% premarket to $163.14.

Olema Pharmaceuticals (OLMA) shares dropped 15.1% to $8.68 after AstraZeneca's SERENA-4 trial failed to meet its primary endpoint. The trial tested camizestrant, which has a similar mechanism to Olema's lead candidate, palazestrant. Stifel cut its price target for Olema to $30 from $48, maintaining a Buy rating. Investors await results from Olema's OPERA-01 trial.

AstraZeneca's experimental breast cancer drug, camizestrant, failed a late-stage trial. Citi maintained a 'buy' rating and £178 target price, citing investor preparedness and the drug's potential in other uses. The stock showed minimal movement. Citi noted the failure reduces the drug's valuation by about 2.5% but is offset by positive outlooks for other trials and AstraZeneca's strong pipeline.

AstraZeneca reported eight-year results from the ADAURA trial, showing Tagrisso (osimertinib) reduced death risk by 47-48% vs. placebo in early-stage EGFRm NSCLC patients. 74-79% of Tagrisso patients were alive at eight years. Data was presented at the IASLC 2026 World Conference on Lung Cancer and published in the Journal of Thoracic Oncology. According to AstraZeneca, this reinforces Tagrisso as the standard of care.

AstraZeneca's cancer drug camizestrant missed the primary endpoint in the SERENA-4 trial for first-line breast cancer, though shares rose 3.4% to 12,106p. The drug showed numerical improvement in progression-free survival but lacked statistical significance. The company plans to focus on other trials and approved uses. The stock is within its 52-week range of 9,826.66p to 15,467.70p.

AstraZeneca's SERENA-4 Phase III trial of Etcamah (camizestrant) with palbociclib did not meet the primary endpoint of progression-free survival in advanced ER-positive breast cancer, though a numerical improvement was observed. The trial compared the combination to anastrozole with palbociclib. Etcamah's safety profile was consistent with known profiles, and data will be shared later. Etcamah is approved in combination with CDK4/6 inhibitors for certain breast cancer treatments.